Marco Soriani, a former microbial cellular biologist, currently acts as Project Director at Reithera Srl. In this role, he leads and coordinates projects for external customers interested in exploiting ReiThera’s know-how and product development capabilities for advanced therapies and vaccines.
Prior this experience, except for 10 years spent in academia, in the last 20 years he has been part of the biotech world as R&D Project Leader and Unit Head at Novartis Vaccines and GSK Vaccines.
In this role, he devoted many energies to create an international and local scientific network to access to crucial innovative technologies.
Regarding his scientific background, after qualifying in Biology at La Sapienza University in Rome, he studied for a doctoral degree in Biochemistry at the University of Zurich.
In 1996, he began a post-doctoral tenure at the Swiss Institute for Experimental Cancer Research, Lausanne (Switzerland) and then moved to UK as a researcher at the University of Bristol (UK).
In 2002, he joined Rino Rappuoli’s team at the Vaccine Research Centre in Siena. During this period, he has built a prestigious career in the vaccine business, reaching important objectives in the R&D context from the discovery on novel vaccine candidates to the direction of scientific programs.
Marco Soriani is author of more than sixty scientific papers in high-ranking international journals and he has been in the board of several EU projects and currently acts as evaluator for EU funding programmes such as Marie Curie Fellowships, ITN and EID.
In 2017, he has obtained the National Scientific Qualification as Full Professor in Microbiology.